415 related articles for article (PubMed ID: 15031776)
21. A new association of ethinylestradiol (0.035 mg) cyproterone acetate (2 mg) in the therapy of polycystic ovary syndrome.
Falsetti L; Dordoni D; Gastaldi C; Gastaldi A
Acta Eur Fertil; 1986; 17(1):19-25. PubMed ID: 2941960
[TBL] [Abstract][Full Text] [Related]
22. Treatment of severe hirsutism resulting from hyperandrogenism with the reverse sequential cyproterone acetate regimen.
Garner PR; Poznanski N
J Reprod Med; 1984 Apr; 29(4):232-6. PubMed ID: 6232380
[TBL] [Abstract][Full Text] [Related]
23. Effects of a low-dose estrogen-antiandrogen combination (Diane-35) on clinical signs of androgenization, hormone profile and ovarian size in patients with polycystic ovary syndrome.
Prelević GM; Würzburger MI; Balint-Perić L; Puzigaća Z
Gynecol Endocrinol; 1989 Dec; 3(4):269-80. PubMed ID: 2516704
[TBL] [Abstract][Full Text] [Related]
24. Decreased melatonin secretion in a phenotypically male 46,XX patient with classic 21-hydroxylase deficiency.
Luboshitzky R; Qupti G; Shen-Orr Z; Hardoff R
Exp Clin Endocrinol Diabetes; 2000; 108(3):237-40. PubMed ID: 10926323
[TBL] [Abstract][Full Text] [Related]
25. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome.
Mitkov M; Pehlivanov B; Terzieva D
Eur J Obstet Gynecol Reprod Biol; 2005 Feb; 118(2):209-13. PubMed ID: 15653205
[TBL] [Abstract][Full Text] [Related]
26. Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial.
Leelaphiwat S; Jongwutiwes T; Lertvikool S; Tabcharoen C; Sukprasert M; Rattanasiri S; Weerakiet S
J Obstet Gynaecol Res; 2015 Mar; 41(3):402-10. PubMed ID: 25319761
[TBL] [Abstract][Full Text] [Related]
27. Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses.
Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Sanchón R; San Millán JL; Escobar-Morreale HF
Diabetes Care; 2007 Sep; 30(9):2309-13. PubMed ID: 17536071
[TBL] [Abstract][Full Text] [Related]
28. [The effects of oxidative stress to PCOS].
Zhang D; Luo WY; Liao H; Wang CF; Sun Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 May; 39(3):421-3. PubMed ID: 18575330
[TBL] [Abstract][Full Text] [Related]
29. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance.
Lemay A; Dodin S; Turcot L; Déchêne F; Forest JC
Hum Reprod; 2006 Jan; 21(1):121-8. PubMed ID: 16199428
[TBL] [Abstract][Full Text] [Related]
30. Hormonal and clinical effects of GnRH agonist alone, or in combination with a combined oral contraceptive or flutamide in women with severe hirsutism.
De Leo V; Fulghesu AM; la Marca A; Morgante G; Pasqui L; Talluri B; Torricelli M; Caruso A
Gynecol Endocrinol; 2000 Dec; 14(6):411-6. PubMed ID: 11228061
[TBL] [Abstract][Full Text] [Related]
31. The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms - a review.
Bitzer J; Römer T; Lopes da Silva Filho A
Eur J Contracept Reprod Health Care; 2017 Jun; 22(3):172-182. PubMed ID: 28447864
[TBL] [Abstract][Full Text] [Related]
32. Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate.
Armstrong VL; Wiggam MI; Ennis CN; Sheridan B; Traub AI; Atkinson AB; Bell PM
QJM; 2001 Jan; 94(1):31-7. PubMed ID: 11161134
[TBL] [Abstract][Full Text] [Related]
33. Salivary testosterone as an index of antiandrogen therapy in hirsutism.
Gómez JM; Navarro MA; Arranz B; Soler J; Bonnin MR; Montaña E
Recenti Prog Med; 1992 Dec; 83(12):672-4. PubMed ID: 1494704
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism.
Batukan C; Muderris II
Fertil Steril; 2006 Feb; 85(2):436-40. PubMed ID: 16595223
[TBL] [Abstract][Full Text] [Related]
35. Spironolactone as a single agent for long-term therapy of hirsute patients.
Spritzer PM; Lisboa KO; Mattiello S; Lhullier F
Clin Endocrinol (Oxf); 2000 May; 52(5):587-94. PubMed ID: 10792338
[TBL] [Abstract][Full Text] [Related]
36. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
Morin-Papunen L; Vauhkonen I; Koivunen R; Ruokonen A; Martikainen H; Tapanainen JS
J Clin Endocrinol Metab; 2003 Jan; 88(1):148-56. PubMed ID: 12519844
[TBL] [Abstract][Full Text] [Related]
37. A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome.
Mhao NS; Al-Hilli AS; Hadi NR; Jamil DA; Al-Aubaidy HA
Diabetes Metab Syndr; 2016; 10(1 Suppl 1):S95-8. PubMed ID: 26703220
[TBL] [Abstract][Full Text] [Related]
38. Treatment of hyperandrogenism in women with ethinylestradiol and cyproteroneacetate.
Mueck AO;
Eur J Contracept Reprod Health Care; 2017 Jun; 22(3):170-171. PubMed ID: 28540758
[No Abstract] [Full Text] [Related]
39. Treatment of idiopathic hirsute women with two combinations of cyproterone acetate.
Salva P; Morer F; Ordoñez J; Rodriguez J
Int J Clin Pharmacol Res; 1983; 3(2):129-35. PubMed ID: 6237068
[TBL] [Abstract][Full Text] [Related]
40. A detailed investigation of hirsutism in a Turkish population: idiopathic hyperandrogenemia as a perplexing issue.
Unluhizarci K; Gokce C; Atmaca H; Bayram F; Kelestimur F
Exp Clin Endocrinol Diabetes; 2004 Oct; 112(9):504-9. PubMed ID: 15505757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
